Distinct responses of COL17A1 nonsense variants to readthrough drugs and NOG as a novel enhancer in junctional epidermolysis bullosa
Yan Tan, Haifa El Mabrouk, Rui Zhang, Sato Magassa, Cristina Has, Saliha Beyza Sayar · 2026
Read Distinct responses of COL17A1 nonsense variants to readthrough drugs and NOG as a novel enhancer in junctional epidermolysis bullosa by Yan Tan, Haifa El Mabrouk, Rui Zhang, Sato Magassa, Cristina Has, Saliha Beyza Sayar (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13628650.txt.
Description
Children with junctional epidermolysis bullosa tear their skin at a touch, and about a fifth of cases trace to nonsense mutations that cut a key skin protein short. Yan Tan and co-authors test drugs meant to make the cell read through those stop signals, using skin cells grown from patients with different mutations in the COL17A1 gene. The drugs did not work evenly: each variant answered differently. A compound called NOG, which slows the cell's destruction of faulty messages, was tried as a booster beside the readthrough drugs and beside a cocktail the team had built earlier.
The results argue for matching the drug to the mutation rather than prescribing one recipe for all. The authors frame that personalization as the path toward clinic-ready treatments for this form of the disease.
Catalog record
| CREATOR | Yan Tan, Haifa El Mabrouk, Rui Zhang, Sato Magassa, Cristina Has, Saliha Beyza Sayar |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |